새로 진단된 고위험 신경모세포종 아동 치료를 위한 화학요법, 수술 및 줄기세포 이식을 병용한 디누툭시맙
새로 진단된 고위험 신경모세포종 아동을 위한 집중 복합요법에 디누툭시맙을 추가한 제3상 연구
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
- 의약품: Carboplatin
- 의약품: Cyclophosphamide
- 의약품: Cisplatin
- 절차: Bone Marrow Biopsy
- 의약품: Doxorubicin
- 의약품: Vincristine
- 절차: Magnetic Resonance Imaging
- 절차: Echocardiography Test
- 절차: Multigated Acquisition Scan
- 절차: Bone Marrow Aspiration
- 의약품: Etoposide
- 절차: Computed Tomography
- 의약품: Topotecan
- 방사능: Radiation Therapy
- 절차: Biospecimen Collection
- 다른: Survey Administration
- 의약품: Melphalan
- 의약품: Irinotecan
- 의약품: Thiotepa
- 생물학적: Dinutuximab
- 절차: FDG-Positron Emission Tomography and Computed Tomography Scan
- 절차: Hematopoietic Cell Transplantation
- 의약품: Isotretinoin
- 절차: Leukapheresis
- 절차: Radionuclide Imaging
- 의약품: Temozolomide
- 절차: Tumor Resection
상세 설명
PRIMARY OBJECTIVE:
I. To determine if the event-free survival (EFS) of patients with newly diagnosed high-risk neuroblastoma assigned to early chemoimmunotherapy during Induction differs from that of patients who are not assigned to treatment that includes early chemoimmunotherapy.
SECONDARY OBJECTIVES:
I. To determine if early chemoimmunotherapy during Induction therapy improves end of Induction (EOI) response rates and overall survival (OS) for patients with newly diagnosed high-risk neuroblastoma.
II. To determine response rates, EFS, and OS following an Extended Induction regimen with chemoimmunotherapy in patients with progressive disease or a poor response to Induction therapy.
III. To compare the toxicities experienced by patients treated with chemoimmunotherapy during Induction versus those experienced by patients treated with standard Induction and to describe toxicities experienced during Extended Induction.
IV. To determine GD2 expression on tumor tissue and tumor cells in bone marrow and assess for associations with response and outcome.
EXPLORATORY OBJECTIVES:
I. To describe the association between tumor and host factors and outcomes in patients receiving protocol therapy.
II. To evaluate circulating biomarkers and markers of minimal residual disease at baseline and during therapy, and assess for associations with response and outcome.
III. To compare patterns of failure between patients treated with and without dinutuximab during induction.
IV. To determine the effect of telomere maintenance mechanisms on end of Induction response rates, EFS, and OS.
V. To explore the impact of high-risk neuroblastoma (HRNBL) and its therapy, including the addition of dinutuximab to Induction chemotherapy, on functional and quality of life outcomes in patients with HRNBL, as measured by caregiver (parent/legal guardian) and patient questionnaires.
VI. To describe the adequacy of diagnostic biopsy specimens, including those obtained by percutaneous core needle biopsy.
VII. To explore the associations between family-reported adverse social determinants of health and both clinical outcomes and biology.
VIII. To develop and validate deep learning predictors of Induction response based on diagnostic MIBG scans. (Imaging Objective) IX. To compare institutional versus central determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and poor end of induction response (PEIR) and good end of induction response (GEIR) determination. (Imaging Objective) X. To describe late toxicities (including impaired organ function, neuropsychiatric toxicity, and incidence of secondary malignancy) in patients treated with dinutuximab during Induction or Extended Induction to late toxicities in patients who have not received dinutuximab during these phases of therapy.
XI. To evaluate whether reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts.
XII. To compare post-transplant complications between treatment arms, and assess for associations with outcome.
XIII. To assess for associations between EOI response (including good end of Induction response [GEIR] and poor end of Induction response [PEIR]) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS).
XIV. To describe and compare the changes in image-defined risk factors (IDRFs) between patients treated with and without dinutuximab during Induction and associate with surgical outcomes and local failure rates following primary tumor resection.
XV. To bank serial samples of blood, bone marrow, and tumor tissue for future research.
OUTLINE: Patients receive Induction cycle 1 and are then randomized to 1 of 2 treatment arms.
INDUCTION CYCLE 1: Patients receive cyclophosphamide intravenously (IV) over 30 minutes and topotecan IV over 30 minutes on days 1-5 in the absence of unacceptable toxicity.
ARM A:
INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes and topotecan IV over 30 minutes on days 1-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients then receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.
EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide orally (PO), via nasogastric tube (NG), or via gastric tube (G-tube) on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.
CONSOLIDATION: Patients undergo two autologous hematopoietic stem cell transplantations (HSCTs) during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion, patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2. Patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.
POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO twice daily (BID) on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.
Patients undergo blood and urine sample collection, echocardiogram (ECHO) or multigated acquisition scan (MUGA), bone marrow aspiration and/or biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), iodine-123 meta-iodobenzylguanidine (I-MIBG) scan and possible fluorodeoxyglucose position emission tomography (FDG-PET) scan throughout the study.
ARM B:
INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes, topotecan IV over 30 minutes on days 1-5, and dinutuximab IV over 10 hours on days 2-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 and dinutuximab IV over 10 hours on days 2-5 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2, and dinutuximab IV over 10 hours on days 2-5 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.
EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide PO, via NG tube, or via G-tube on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.
CONSOLIDATION: Patients undergo two autologous HSCTs during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2, patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.
POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO BID on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.
Patients undergo blood and urine sample collection, ECHO or MUGA, bone marrow aspiration and/or biopsy, CT scan, MRI, I-MIBG scan and possible FDG-PET scan throughout the study.
After completion of study treatment, patients are followed up at 3, 6, 9,12, 15, 18, 24, 30, 36, 42, 48, 54, and 60 months and then periodically for up to 10 years from enrollment.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 장소
-
-
Auckland
-
Grafton, Auckland, 뉴질랜드, 1145
- 모병
- Starship Children's Hospital
-
수석 연구원:
- Andrew C. Wood
-
연락하다:
- Site Public Contact
- 전화번호: 0800 728 436
-
-
-
-
Alabama
-
Birmingham, Alabama, 미국, 35233
- 모병
- Children's Hospital of Alabama
-
연락하다:
- Site Public Contact
- 전화번호: 205-638-9285
- 이메일: oncologyresearch@peds.uab.edu
-
수석 연구원:
- Elizabeth D. Alva
-
Mobile, Alabama, 미국, 36604
- 모병
- USA Health Strada Patient Care Center
-
연락하다:
- Site Public Contact
- 전화번호: 800-388-8721
-
수석 연구원:
- Hamayun Imran
-
-
Arizona
-
Mesa, Arizona, 미국, 85202
- 모병
- Banner Children's at Desert
-
연락하다:
- Site Public Contact
- 전화번호: 480-412-3100
-
수석 연구원:
- Joseph C. Torkildson
-
Phoenix, Arizona, 미국, 85016
- 모병
- Phoenix Childrens Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 602-546-0920
-
수석 연구원:
- Alok K. Kothari
-
Tucson, Arizona, 미국, 85719
- 모병
- Banner University Medical Center - Tucson
-
연락하다:
- Site Public Contact
- 이메일: UACC-IIT@uacc.arizona.edu
-
수석 연구원:
- Monica M. Davini
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72202-3591
- 모병
- Arkansas Children's Hospital
-
수석 연구원:
- Michael W. Bishop
-
연락하다:
- Site Public Contact
- 전화번호: 501-364-7373
-
-
California
-
Downey, California, 미국, 90242
- 모병
- Kaiser Permanente Downey Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 626-564-3455
-
수석 연구원:
- Robert M. Cooper
-
Duarte, California, 미국, 91010
- 모병
- City of Hope Comprehensive Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 800-826-4673
- 이메일: becomingapatient@coh.org
-
수석 연구원:
- Hung C. Tran
-
Loma Linda, California, 미국, 92354
- 모병
- Loma Linda University Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 909-558-4050
-
수석 연구원:
- Albert Kheradpour
-
Long Beach, California, 미국, 90806
- 모병
- Miller Children's and Women's Hospital Long Beach
-
연락하다:
- Site Public Contact
- 전화번호: 562-933-5600
-
수석 연구원:
- Jacqueline N. Casillas
-
Los Angeles, California, 미국, 90027
- 모병
- Children's Hospital Los Angeles
-
연락하다:
- Site Public Contact
- 전화번호: 323-361-4110
-
수석 연구원:
- Araz Marachelian
-
Los Angeles, California, 미국, 90048
- 모병
- Cedars-Sinai Medical Center
-
수석 연구원:
- Fataneh (Fae) Majlessipour
-
연락하다:
- Site Public Contact
- 전화번호: 310-423-2133
- 이메일: Cancer.trial.info@cshs.org
-
Los Angeles, California, 미국, 90095
- 모병
- Mattel Children's Hospital UCLA
-
연락하다:
- Site Public Contact
- 전화번호: 310-825-6708
-
수석 연구원:
- Satiro N. De Oliveira
-
Madera, California, 미국, 93636
- 모병
- Valley Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 559-353-3000
- 이메일: Research@valleychildrens.org
-
수석 연구원:
- Ruetima Titapiwatanakun
-
Oakland, California, 미국, 94611
- 모병
- Kaiser Permanente-Oakland
-
연락하다:
- Site Public Contact
- 전화번호: 877-642-4691
- 이메일: Kpoct@kp.org
-
수석 연구원:
- Aarati V. Rao
-
Oakland, California, 미국, 94609
- 모병
- UCSF Benioff Children's Hospital Oakland
-
수석 연구원:
- Jennifer G. Michlitsch
-
연락하다:
- Site Public Contact
- 전화번호: 510-428-3264
- 이메일: PedOncRschOAK@ucsf.edu
-
Orange, California, 미국, 92868
- 모병
- Children's Hospital of Orange County
-
연락하다:
- Site Public Contact
- 전화번호: 714-509-8646
- 이메일: oncresearch@choc.org
-
수석 연구원:
- Elyssa M. Rubin
-
Palo Alto, California, 미국, 94304
- 모병
- Lucile Packard Children's Hospital Stanford University
-
연락하다:
- Site Public Contact
- 전화번호: 800-694-0012
- 이메일: ccto-office@stanford.edu
-
수석 연구원:
- Jay Michael S. Balagtas
-
Sacramento, California, 미국, 95817
- 모병
- University of California Davis Comprehensive Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 916-734-3089
-
수석 연구원:
- Marcio H. Malogolowkin
-
Sacramento, California, 미국, 95816
- 모병
- Sutter Medical Center Sacramento
-
연락하다:
- Site Public Contact
- 이메일: clinicalresearch@sutterhealth.org
-
수석 연구원:
- Sandra Baril
-
San Diego, California, 미국, 92123
- 모병
- Rady Children's Hospital - San Diego
-
연락하다:
- Site Public Contact
- 전화번호: 858-966-5934
-
수석 연구원:
- William D. Roberts
-
San Francisco, California, 미국, 94158
- 모병
- UCSF Medical Center-Mission Bay
-
연락하다:
- Site Public Contact
- 전화번호: 877-827-3222
- 이메일: cancertrials@ucsf.edu
-
수석 연구원:
- Arun A. Rangaswami
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 모병
- Children's Hospital Colorado
-
수석 연구원:
- Navin R. Pinto
-
연락하다:
- Site Public Contact
- 전화번호: 303-764-5056
- 이메일: josh.b.gordon@nsmtp.kp.org
-
-
Connecticut
-
Hartford, Connecticut, 미국, 06106
- 모병
- Connecticut Children's Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 860-545-9981
-
수석 연구원:
- Michael S. Isakoff
-
New Haven, Connecticut, 미국, 06520
- 모병
- Yale University
-
연락하다:
- Site Public Contact
- 전화번호: 203-785-5702
- 이메일: canceranswers@yale.edu
-
수석 연구원:
- Farzana Pashankar
-
-
Delaware
-
Wilmington, Delaware, 미국, 19803
- 모병
- Alfred I duPont Hospital for Children
-
연락하다:
- Site Public Contact
- 전화번호: 302-651-5572
- 이메일: Allison.bruce@nemours.org
-
수석 연구원:
- Sridhi Patel
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20010
- 모병
- Children's National Medical Center
-
수석 연구원:
- Jeffrey S. Dome
-
연락하다:
- Site Public Contact
- 전화번호: 202-476-2800
- 이메일: OncCRC_OnCall@childrensnational.org
-
-
Florida
-
Fort Lauderdale, Florida, 미국, 33316
- 모병
- Broward Health Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 302-651-5572
- 이메일: Allison.bruce@nemours.org
-
수석 연구원:
- Hector M. Rodriguez-Cortes
-
Fort Myers, Florida, 미국, 33908
- 모병
- Golisano Children's Hospital of Southwest Florida
-
연락하다:
- Site Public Contact
- 전화번호: 239-343-5333
- 이메일: molly.arnstrom@leehealth.org
-
수석 연구원:
- Emad K. Salman
-
Gainesville, Florida, 미국, 32610
- 모병
- UF Health Cancer Institute - Gainesville
-
연락하다:
- Site Public Contact
- 전화번호: 352-273-8010
- 이메일: cancer-center@ufl.edu
-
수석 연구원:
- Brian Stover
-
Hollywood, Florida, 미국, 33021
- 모병
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 954-265-1847
- 이메일: OHR@mhs.net
-
수석 연구원:
- Iftikhar Hanif
-
Jacksonville, Florida, 미국, 32207
- 모병
- Nemours Children's Clinic-Jacksonville
-
연락하다:
- Site Public Contact
- 전화번호: 302-651-5572
- 이메일: Allison.bruce@nemours.org
-
수석 연구원:
- Sridhi Patel
-
Miami, Florida, 미국, 33155
- 모병
- Nicklaus Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 888-624-2778
-
수석 연구원:
- Ziad A. Khatib
-
Miami, Florida, 미국, 33136
- 모병
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 305-243-2647
-
수석 연구원:
- Meghan McCormick
-
Orlando, Florida, 미국, 32806
- 모병
- Arnold Palmer Hospital for Children
-
연락하다:
- Site Public Contact
- 전화번호: 321-841-5357
- 이메일: Jennifer.spinelli@orlandohealth.com
-
수석 연구원:
- Zhongbo Hu
-
Orlando, Florida, 미국, 32827
- 모병
- Nemours Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 302-651-5572
- 이메일: Allison.bruce@nemours.org
-
수석 연구원:
- Sridhi Patel
-
Orlando, Florida, 미국, 32803
- 모병
- AdventHealth Orlando
-
연락하다:
- Site Public Contact
- 전화번호: 407-303-2090
- 이메일: FH.Cancer.Research@flhosp.org
-
수석 연구원:
- Fouad M. Hajjar
-
St. Petersburg, Florida, 미국, 33701
- 모병
- Johns Hopkins All Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 727-767-4784
- 이메일: Ashley.Repp@jhmi.edu
-
수석 연구원:
- Jennifer B. Dean
-
West Palm Beach, Florida, 미국, 33407
- 모병
- Saint Mary's Medical Center
-
수석 연구원:
- Matthew D. Ramirez
-
연락하다:
- Site Public Contact
- 전화번호: 561-822-4745
-
-
Georgia
-
Atlanta, Georgia, 미국, 30329
- 모병
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
수석 연구원:
- William T. Cash
-
연락하다:
- Site Public Contact
- 전화번호: 404-785-0232
- 이메일: Olivia.Floyd@choa.org
-
Savannah, Georgia, 미국, 31404
- 모병
- Memorial Health University Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 912-350-7887
- 이메일: Lorraine.OHara@hcahealthcare.com
-
수석 연구원:
- James N. Yarnall
-
-
Hawaii
-
Honolulu, Hawaii, 미국, 96826
- 모병
- Kapiolani Medical Center for Women and Children
-
연락하다:
- Site Public Contact
- 전화번호: 808-983-6090
-
수석 연구원:
- Wade T. Kyono
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- 모병
- Lurie Children's Hospital-Chicago
-
연락하다:
- Site Public Contact
- 전화번호: 773-880-4562
-
수석 연구원:
- Elizabeth A. Sokol
-
Chicago, Illinois, 미국, 60637
- 모병
- University of Chicago Comprehensive Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 773-702-8222
- 이메일: cancerclinicaltrials@bsd.uchicago.edu
-
수석 연구원:
- Ami V. Desai
-
Chicago, Illinois, 미국, 60612
- 모병
- University of Illinois
-
연락하다:
- Site Public Contact
- 전화번호: 312-355-3046
-
수석 연구원:
- Dipti S. Dighe
-
Oak Lawn, Illinois, 미국, 60453
- 모병
- Advocate Children's Hospital-Oak Lawn
-
연락하다:
- Site Public Contact
- 전화번호: 847-723-7570
-
수석 연구원:
- Rebecca E. McFall
-
Park Ridge, Illinois, 미국, 60068
- 모병
- Advocate Children's Hospital-Park Ridge
-
연락하다:
- Site Public Contact
- 이메일: helpdesk@childrensoncologygroup.org
-
수석 연구원:
- Rebecca E. McFall
-
Peoria, Illinois, 미국, 61637
- 모병
- OSF Children's Hospital of Illinois
-
수석 연구원:
- Prerna Kumar
-
연락하다:
- Site Public Contact
- 전화번호: 309-624-4945
- 이메일: ChildrensHospitalofIllinois@osfhealthcare.org
-
Springfield, Illinois, 미국, 62702
- 모병
- Southern Illinois University School of Medicine
-
연락하다:
- Site Public Contact
- 전화번호: 217-545-7929
-
수석 연구원:
- Gregory P. Brandt
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202
- 모병
- Riley Hospital for Children
-
연락하다:
- Site Public Contact
- 전화번호: 800-248-1199
-
수석 연구원:
- Marissa Just
-
Indianapolis, Indiana, 미국, 46260
- 모병
- Ascension Saint Vincent Indianapolis Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 317-338-2194
- 이메일: research@stvincent.org
-
수석 연구원:
- Bassem I. Razzouk
-
-
Iowa
-
Des Moines, Iowa, 미국, 50309
- 모병
- Blank Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 515-241-8912
- 이메일: samantha.mallory@unitypoint.org
-
수석 연구원:
- Samantha L. Mallory
-
Iowa City, Iowa, 미국, 52242
- 모병
- University of Iowa/Holden Comprehensive Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 800-237-1225
-
수석 연구원:
- Andrew P. Groves
-
-
Kansas
-
Wichita, Kansas, 미국, 67214
- 모병
- Wesley Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 316-962-7802
- 이메일: WesleyResearch@wesleymc.com
-
수석 연구원:
- Nathan S. Hall
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40536
- 모병
- University of Kentucky/Markey Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 859-257-3379
-
수석 연구원:
- James T. Badgett
-
Louisville, Kentucky, 미국, 40202
- 모병
- Norton Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 502-629-5500
- 이메일: CancerResource@nortonhealthcare.org
-
수석 연구원:
- Michael J. Ferguson
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70118
- 모병
- Children's Hospital New Orleans
-
수석 연구원:
- Maria C. Velez-Yanguas
-
연락하다:
- Site Public Contact
- 전화번호: 504-894-5377
-
-
Maine
-
Bangor, Maine, 미국, 04401
- 모병
- Eastern Maine Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 207-973-4274
-
수석 연구원:
- Daniel L. Callaway
-
Scarborough, Maine, 미국, 04074
- 모병
- Maine Children's Cancer Program
-
수석 연구원:
- Sei-Gyung K. Sze
-
연락하다:
- Site Public Contact
- 전화번호: 207-396-8670
- 이메일: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- 모병
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
수석 연구원:
- Allen R. Chen
-
연락하다:
- Site Public Contact
- 전화번호: 410-955-8804
- 이메일: jhcccro@jhmi.edu
-
Baltimore, Maryland, 미국, 21215
- 모병
- Sinai Hospital of Baltimore
-
수석 연구원:
- Jason M. Fixler
-
연락하다:
- Site Public Contact
- 전화번호: 410-601-9083
-
Baltimore, Maryland, 미국, 21201
- 모병
- University of Maryland/Greenebaum Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 800-888-8823
-
수석 연구원:
- Teresa A. York
-
Bethesda, Maryland, 미국, 20889-5600
- 모병
- Walter Reed National Military Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 301-319-2100
-
수석 연구원:
- Kip R. Hartman
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- 모병
- Massachusetts General Hospital Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 877-726-5130
-
수석 연구원:
- Lauren H. Boal
-
Boston, Massachusetts, 미국, 02215
- 모병
- Dana-Farber Cancer Institute
-
연락하다:
- Site Public Contact
- 전화번호: 877-442-3324
-
수석 연구원:
- Suzanne Shusterman
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 모병
- C S Mott Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 800-865-1125
-
수석 연구원:
- Rajen Mody
-
Detroit, Michigan, 미국, 48201
- 정지된
- Children's Hospital of Michigan
-
Grand Rapids, Michigan, 미국, 49503
- 모병
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 616-391-1230
- 이메일: crcwm-regulatory@crcwm.org
-
수석 연구원:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, 미국, 49007
- 모병
- Bronson Methodist Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 616-391-1230
- 이메일: crcwm-regulatory@crcwm.org
-
수석 연구원:
- Kathleen Y. Butler
-
Royal Oak, Michigan, 미국, 48073
- 모병
- Corewell Health Children's
-
연락하다:
- Site Public Contact
- 전화번호: 248-551-7695
-
수석 연구원:
- Marie V. Nelson
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55404
- 모병
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
수석 연구원:
- Michael K. Richards
-
연락하다:
- Site Public Contact
- 전화번호: 612-813-5913
- 이메일: pauline.mitby@childrensmn.org
-
Minneapolis, Minnesota, 미국, 55455
- 모병
- University of Minnesota/Masonic Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 612-624-2620
-
수석 연구원:
- Robin L. Williams
-
Rochester, Minnesota, 미국, 55905
- 모병
- Mayo Clinic in Rochester
-
연락하다:
- Site Public Contact
- 전화번호: 855-776-0015
-
수석 연구원:
- Peter Schoettler
-
-
Mississippi
-
Jackson, Mississippi, 미국, 39216
- 모병
- University of Mississippi Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 601-815-6700
-
수석 연구원:
- Amanda Strobel
-
-
Missouri
-
Columbia, Missouri, 미국, 65212
- 모병
- University of Missouri Children's Hospital
-
수석 연구원:
- Barbara A. Gruner
-
연락하다:
- Site Public Contact
- 전화번호: 573-882-1960
- 이메일: snwq62@health.missouri.edu
-
Kansas City, Missouri, 미국, 64108
- 모병
- Children's Mercy Hospitals and Clinics
-
수석 연구원:
- Keith J. August
-
연락하다:
- Site Public Contact
- 전화번호: 816-302-6808
- 이메일: COGResearchGroup@cmh.edu
-
St Louis, Missouri, 미국, 63110
- 모병
- Washington University School of Medicine
-
연락하다:
- Site Public Contact
- 전화번호: 800-600-3606
- 이메일: info@siteman.wustl.edu
-
수석 연구원:
- Frederick S. Huang
-
St Louis, Missouri, 미국, 63141
- 모병
- Mercy Hospital Saint Louis
-
연락하다:
- Site Public Contact
- 전화번호: 314-251-7066
-
수석 연구원:
- Robin D. Hanson
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68114
- 모병
- Children's Hospital and Medical Center of Omaha
-
연락하다:
- Site Public Contact
- 전화번호: 402-955-3949
-
수석 연구원:
- Jill C. Beck
-
Omaha, Nebraska, 미국, 68198
- 모병
- University of Nebraska Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 402-559-6941
- 이메일: unmcrsa@unmc.edu
-
수석 연구원:
- Jill C. Beck
-
-
Nevada
-
Las Vegas, Nevada, 미국, 89135
- 모병
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
연락하다:
- Site Public Contact
- 전화번호: 702-384-0013
- 이메일: research@sncrf.org
-
수석 연구원:
- Joseph L. Lasky
-
-
New Hampshire
-
Lebanon, New Hampshire, 미국, 03756
- 모병
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
수석 연구원:
- Angela Ricci
-
연락하다:
- Site Public Contact
- 전화번호: 800-639-6918
- 이메일: cancer.research.nurse@dartmouth.edu
-
-
New Jersey
-
Hackensack, New Jersey, 미국, 07601
- 모병
- Hackensack University Medical Center
-
수석 연구원:
- Katharine Offer
-
연락하다:
- Site Public Contact
- 전화번호: 551-996-2897
-
Morristown, New Jersey, 미국, 07960
- 모병
- Morristown Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 973-971-5900
-
수석 연구원:
- Kathryn L. Laurie
-
New Brunswick, New Jersey, 미국, 08901
- 모병
- Saint Peter's University Hospital
-
수석 연구원:
- Nibal A. Zaghloul
-
연락하다:
- Site Public Contact
- 전화번호: 732-745-8600
- 이메일: officeofresearch@saintpetersuh.com
-
New Brunswick, New Jersey, 미국, 08903
- 모병
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 732-235-8675
-
수석 연구원:
- Nehal S. Parikh
-
Newark, New Jersey, 미국, 07112
- 모병
- Newark Beth Israel Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 973-926-7230
- 이메일: Christine.Kosmides@rwjbh.org
-
수석 연구원:
- Teena Bhatla
-
Paterson, New Jersey, 미국, 07503
- 모병
- Saint Joseph's Regional Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 973-754-2207
- 이메일: HallL@sjhmc.org
-
수석 연구원:
- Alissa Kahn
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87106
- 정지된
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, 미국, 12208
- 모병
- Albany Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 518-262-5513
-
수석 연구원:
- Lauren R. Weintraub
-
Buffalo, New York, 미국, 14263
- 모병
- Roswell Park Cancer Institute
-
연락하다:
- Site Public Contact
- 전화번호: 800-767-9355
- 이메일: askroswell@roswellpark.org
-
수석 연구원:
- Clare J. Twist
-
Mineola, New York, 미국, 11501
- 모병
- NYU Langone Hospital - Long Island
-
연락하다:
- Site Public Contact
- 전화번호: 212-263-4432
- 이메일: cancertrials@nyulangone.org
-
수석 연구원:
- Chana L. Glasser
-
New Hyde Park, New York, 미국, 11040
- 모병
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
연락하다:
- Site Public Contact
- 전화번호: 718-470-3460
-
수석 연구원:
- Julie I. Krystal
-
New York, New York, 미국, 10032
- 모병
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
수석 연구원:
- Nobuko Hijiya
-
연락하다:
- Site Public Contact
- 전화번호: 212-342-5162
- 이메일: cancerclinicaltrials@cumc.columbia.edu
-
New York, New York, 미국, 10016
- 모병
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
수석 연구원:
- Elizabeth A. Raetz
-
연락하다:
- Site Public Contact
- 이메일: CancerTrials@nyulangone.org
-
Rochester, New York, 미국, 14642
- 모병
- University of Rochester
-
연락하다:
- Site Public Contact
- 전화번호: 585-275-5830
-
수석 연구원:
- Rafi R. Kazi
-
Syracuse, New York, 미국, 13210
- 모병
- State University of New York Upstate Medical University
-
연락하다:
- Site Public Contact
- 전화번호: 315-464-5476
-
수석 연구원:
- Melanie A. Comito
-
The Bronx, New York, 미국, 10467
- 모병
- Montefiore Medical Center - Moses Campus
-
연락하다:
- Site Public Contact
- 전화번호: 718-379-6866
- 이메일: eskwak@montefiore.org
-
수석 연구원:
- Alice Lee
-
Valhalla, New York, 미국, 10595
- 모병
- New York Medical College
-
연락하다:
- Site Public Contact
- 전화번호: 914-594-3794
-
수석 연구원:
- Andrew J. Bellantoni
-
-
North Carolina
-
Asheville, North Carolina, 미국, 28801
- 모병
- Mission Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 828-213-7055
- 이메일: NCDV.ResearchRegulatory@HCAHealthcare.com
-
수석 연구원:
- Douglas J. Scothorn
-
Chapel Hill, North Carolina, 미국, 27599
- 모병
- UNC Lineberger Comprehensive Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 877-668-0683
- 이메일: cancerclinicaltrials@med.unc.edu
-
수석 연구원:
- Thomas B. Alexander
-
Charlotte, North Carolina, 미국, 28203
- 모병
- Carolinas Medical Center/Levine Cancer Institute
-
연락하다:
- Site Public Contact
- 전화번호: 800-804-9376
-
수석 연구원:
- Joel A. Kaplan
-
Charlotte, North Carolina, 미국, 28204
- 모병
- Novant Health Presbyterian Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 980-201-6360
- 이메일: kashah@novanthealth.org
-
수석 연구원:
- Holly Edington
-
Durham, North Carolina, 미국, 27710
- 모병
- Duke University Medical Center
-
수석 연구원:
- Jessica M. Sun
-
연락하다:
- Site Public Contact
- 전화번호: 888-275-3853
-
Greenville, North Carolina, 미국, 27834
- 모병
- East Carolina University
-
연락하다:
- Site Public Contact
- 전화번호: 252-744-1015
- 이메일: eubankss@ecu.edu
-
수석 연구원:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, 미국, 27157
- 모병
- Wake Forest University Health Sciences
-
연락하다:
- Site Public Contact
- 전화번호: 336-713-6771
-
수석 연구원:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, 미국, 58122
- 모병
- Sanford Broadway Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 701-323-5760
- 이메일: OncologyClinicalTrialsFargo@sanfordhealth.org
-
수석 연구원:
- Samuel J. Milanovich
-
-
Ohio
-
Akron, Ohio, 미국, 44308
- 모병
- Children's Hospital Medical Center of Akron
-
연락하다:
- Site Public Contact
- 전화번호: 330-543-3193
-
수석 연구원:
- Lauren R. Draper
-
Cincinnati, Ohio, 미국, 45229
- 모병
- Cincinnati Children's Hospital Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 513-636-2799
- 이메일: cancer@cchmc.org
-
수석 연구원:
- Katherine M. Somers
-
Cleveland, Ohio, 미국, 44195
- 모병
- Cleveland Clinic Foundation
-
연락하다:
- Site Public Contact
- 전화번호: 866-223-8100
- 이메일: TaussigResearch@ccf.org
-
수석 연구원:
- Matteo M. Trucco
-
Cleveland, Ohio, 미국, 44106
- 모병
- Rainbow Babies and Childrens Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 216-844-5437
-
수석 연구원:
- Duncan S. Stearns
-
Columbus, Ohio, 미국, 43205
- 모병
- Nationwide Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 614-722-6039
- 이메일: Melinda.Triplet@nationwidechildrens.org
-
수석 연구원:
- Mark A. Ranalli
-
Dayton, Ohio, 미국, 45404
- 모병
- Dayton Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 800-228-4055
-
수석 연구원:
- Jordan M. Wright
-
Toledo, Ohio, 미국, 43606
- 모병
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 419-824-1842
- 이메일: PCIOncResearch@promedica.org
-
수석 연구원:
- Jamie L. Dargart
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73104
- 모병
- University of Oklahoma Health Sciences Center
-
연락하다:
- Site Public Contact
- 전화번호: 405-271-8777
- 이메일: ou-clinical-trials@ouhsc.edu
-
수석 연구원:
- Rene Y. McNall-Knapp
-
Tulsa, Oklahoma, 미국, 74136
- 모병
- Saint Francis Children's Hospital
-
수석 연구원:
- Jill A. Salo
-
연락하다:
- Site Public Contact
- 전화번호: 918-502-6720
-
-
Oregon
-
Portland, Oregon, 미국, 97227
- 모병
- Legacy Emanuel Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 503-413-2560
-
수석 연구원:
- Jason M. Glover
-
Portland, Oregon, 미국, 97239
- 모병
- Oregon Health and Science University
-
연락하다:
- Site Public Contact
- 전화번호: 503-494-1080
- 이메일: trials@ohsu.edu
-
수석 연구원:
- Susan J. Lindemulder
-
-
Pennsylvania
-
Allentown, Pennsylvania, 미국, 18103
- 모병
- Lehigh Valley Hospital-Cedar Crest
-
연락하다:
- Site Public Contact
- 전화번호: 610-402-9543
- 이메일: Morgan_M.Horton@lvhn.org
-
수석 연구원:
- Jacob A. Troutman
-
Danville, Pennsylvania, 미국, 17822
- 모병
- Geisinger Medical Center
-
수석 연구원:
- Jagadeesh Ramdas
-
연락하다:
- Site Public Contact
- 전화번호: 570-271-5251
- 이메일: cancerresearch@geisinger.edu
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- Children's Hospital of Philadelphia
-
수석 연구원:
- Rochelle Bagatell
-
연락하다:
- Site Public Contact
- 전화번호: 267-425-5544
- 이메일: CancerTrials@email.chop.edu
-
Philadelphia, Pennsylvania, 미국, 19134
- 모병
- Saint Christopher's Hospital for Children
-
연락하다:
- Site Public Contact
- 전화번호: 215-427-8991
-
수석 연구원:
- Gregory E. Halligan
-
Pittsburgh, Pennsylvania, 미국, 15224
- 모병
- Children's Hospital of Pittsburgh of UPMC
-
연락하다:
- Site Public Contact
- 전화번호: 412-692-8570
- 이메일: jean.tersak@chp.edu
-
수석 연구원:
- Jean M. Tersak
-
-
Rhode Island
-
Providence, Rhode Island, 미국, 02903
- 모병
- Rhode Island Hospital
-
수석 연구원:
- Bradley DeNardo
-
연락하다:
- Site Public Contact
- 전화번호: 401-444-1488
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- 모병
- Medical University of South Carolina
-
연락하다:
- Site Public Contact
- 전화번호: 843-792-9321
- 이메일: hcc-clinical-trials@musc.edu
-
수석 연구원:
- Jacqueline M. Kraveka
-
Columbia, South Carolina, 미국, 29203
- 모병
- Prisma Health Richland Hospital
-
수석 연구원:
- Stuart L. Cramer
-
연락하다:
- Site Public Contact
- 전화번호: 864-522-4317
- 이메일: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, 미국, 29605
- 모병
- BI-LO Charities Children's Cancer Center
-
수석 연구원:
- Aniket Saha
-
연락하다:
- Site Public Contact
- 전화번호: 864-522-4317
- 이메일: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, 미국, 57117-5134
- 모병
- Sanford USD Medical Center - Sioux Falls
-
연락하다:
- Site Public Contact
- 전화번호: 605-312-3320
- 이메일: OncologyClinicalTrialsSF@SanfordHealth.org
-
수석 연구원:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Knoxville, Tennessee, 미국, 37916
- 모병
- East Tennessee Childrens Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 865-541-8266
-
수석 연구원:
- Susan E. Spiller
-
Memphis, Tennessee, 미국, 38105
- 모병
- Saint Jude Children's Research Hospital
-
수석 연구원:
- Sara M. Federico
-
연락하다:
- Site Public Contact
- 전화번호: 888-226-4343
- 이메일: referralinfo@stjude.org
-
Nashville, Tennessee, 미국, 37232
- 모병
- Vanderbilt University/Ingram Cancer Center
-
수석 연구원:
- Daniel J. Benedetti
-
연락하다:
- Site Public Contact
- 전화번호: 800-811-8480
-
Nashville, Tennessee, 미국, 37203
- 모병
- The Children's Hospital at TriStar Centennial
-
연락하다:
- Site Public Contact
- 전화번호: 615-342-1919
-
수석 연구원:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, 미국, 78723
- 모병
- Dell Children's Medical Center of Central Texas
-
연락하다:
- Site Public Contact
- 전화번호: 512-628-1902
- 이메일: TXAUS-DL-SFCHemonc.research@ascension.org
-
수석 연구원:
- Shannon M. Cohn
-
Corpus Christi, Texas, 미국, 78411
- 모병
- Driscoll Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 361-694-5311
- 이메일: Crystal.DeLosSantos@dchstx.org
-
수석 연구원:
- Nkechi I. Mba
-
Dallas, Texas, 미국, 75390
- 모병
- UT Southwestern/Simmons Cancer Center-Dallas
-
수석 연구원:
- Tanya C. Watt
-
연락하다:
- Site Public Contact
- 전화번호: 214-648-7097
- 이메일: canceranswerline@UTSouthwestern.edu
-
Dallas, Texas, 미국, 75230
- 모병
- Medical City Dallas Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 972-566-5588
-
수석 연구원:
- Maurizio L. Ghisoli
-
El Paso, Texas, 미국, 79905
- 모병
- El Paso Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 915-298-5444
- 이메일: ranjan.bista@ttuhsc.edu
-
수석 연구원:
- Benjamin Carcamo
-
Fort Worth, Texas, 미국, 76104
- 모병
- Cook Children's Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 682-885-2103
- 이메일: CookChildrensResearch@cookchildrens.org
-
수석 연구원:
- Chelsee Greer
-
Houston, Texas, 미국, 77030
- 모병
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 713-798-1354
- 이메일: burton@bcm.edu
-
수석 연구원:
- Jennifer H. Foster
-
Houston, Texas, 미국, 77030
- 모병
- UT MD Anderson Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 866-632-6789
- 이메일: askmdanderson@mdanderson.org
-
수석 연구원:
- Najat C. Daw
-
Lubbock, Texas, 미국, 79410
- 모병
- Covenant Children's Hospital
-
수석 연구원:
- Kishor M. Bhende
-
연락하다:
- Site Public Contact
- 전화번호: 806-725-8657
- 이메일: mbisbee@providence.org
-
Lubbock, Texas, 미국, 79415
- 모병
- UMC Cancer Center / UMC Health System
-
연락하다:
- Site Public Contact
- 전화번호: 806-775-8590
-
수석 연구원:
- Erin K. Barr
-
San Antonio, Texas, 미국, 78207
- 모병
- Children's Hospital of San Antonio
-
연락하다:
- Site Public Contact
- 전화번호: 210-704-2894
- 이메일: bridget.medina@christushealth.org
-
수석 연구원:
- Julie Voeller
-
San Antonio, Texas, 미국, 78229
- 모병
- University of Texas Health Science Center at San Antonio
-
연락하다:
- Site Public Contact
- 전화번호: 210-450-3800
- 이메일: phoresearchoffice@uthscsa.edu
-
수석 연구원:
- Aaron J. Sugalski
-
San Antonio, Texas, 미국, 78229
- 모병
- Methodist Children's Hospital of South Texas
-
연락하다:
- Site Public Contact
- 전화번호: 210-575-6240
- 이메일: Vinod.GidvaniDiaz@hcahealthcare.com
-
수석 연구원:
- Jose M. Esquilin
-
-
Utah
-
Salt Lake City, Utah, 미국, 84113
- 모병
- Primary Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 801-585-5270
-
수석 연구원:
- Leonora R. Slatnick
-
-
Vermont
-
Burlington, Vermont, 미국, 05405
- 모병
- University of Vermont and State Agricultural College
-
연락하다:
- Site Public Contact
- 전화번호: 802-656-8990
- 이메일: rpo@uvm.edu
-
수석 연구원:
- Jessica L. Heath
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22908
- 모병
- University of Virginia Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 434-243-6303
- 이메일: uvacancertrials@hscmail.mcc.virginia.edu
-
수석 연구원:
- Brian C. Belyea
-
Portsmouth, Virginia, 미국, 23708-2197
- 모병
- Naval Medical Center - Portsmouth
-
연락하다:
- Site Public Contact
- 전화번호: 757-953-5939
-
수석 연구원:
- Karin Brockman
-
-
Washington
-
Seattle, Washington, 미국, 98105
- 모병
- Seattle Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 866-987-2000
-
수석 연구원:
- Sarah E. Leary
-
Spokane, Washington, 미국, 99204
- 모병
- Providence Sacred Heart Medical Center and Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 800-228-6618
- 이메일: HopeBeginsHere@providence.org
-
수석 연구원:
- Judy L. Felgenhauer
-
Tacoma, Washington, 미국, 98405
- 모병
- Mary Bridge Children's Hospital and Health Center
-
연락하다:
- Site Public Contact
- 전화번호: 253-403-1461
- 이메일: research@multicare.org
-
수석 연구원:
- Robert G. Irwin
-
-
West Virginia
-
Huntington, West Virginia, 미국, 25701
- 모병
- Edwards Comprehensive Cancer Center
-
수석 연구원:
- Mark A. Ranalli
-
연락하다:
- Site Public Contact
- 전화번호: 304-399-6566
- 이메일: Christina.Cole@chhi.org
-
Morgantown, West Virginia, 미국, 26506
- 모병
- West Virginia University Healthcare
-
연락하다:
- Site Public Contact
- 전화번호: 304-293-7374
- 이메일: cancertrialsinfo@hsc.wvu.edu
-
수석 연구원:
- Ashley E. Meyer
-
-
Wisconsin
-
Green Bay, Wisconsin, 미국, 54301
- 정지된
- Saint Vincent Hospital Cancer Center Green Bay
-
Madison, Wisconsin, 미국, 53792
- 모병
- University of Wisconsin Carbone Cancer Center - University Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 800-622-8922
- 이메일: clinicaltrials@cancer.wisc.edu
-
수석 연구원:
- Margo L. Hoover-Regan
-
Marshfield, Wisconsin, 미국, 54449
- 모병
- Marshfield Medical Center-Marshfield
-
연락하다:
- Site Public Contact
- 전화번호: 800-782-8581
- 이메일: oncology.clinical.trials@marshfieldresearch.org
-
수석 연구원:
- Michelle A. Manalang
-
Milwaukee, Wisconsin, 미국, 53226
- 모병
- Children's Hospital of Wisconsin
-
수석 연구원:
- Angela Steineck
-
연락하다:
- Site Public Contact
- 전화번호: 414-955-4727
- 이메일: MACCCTO@mcw.edu
-
-
-
-
-
Québec, 캐나다, G1V 4G2
- 모병
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
수석 연구원:
- Bruno Michon
-
연락하다:
- Site Public Contact
- 전화번호: 418-525-4444
- 이메일: rechclinique@crchudequebec.ulaval.ca
-
-
Alberta
-
Calgary, Alberta, 캐나다, T3B 6A8
- 모병
- Alberta Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 403-220-6898
- 이메일: research4kids@ucalgary.ca
-
수석 연구원:
- Victor A. Lewis
-
Edmonton, Alberta, 캐나다, T6G 2B7
- 모병
- University of Alberta Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 780-407-8798
- 이메일: pedsoncologyresearch@ahs.ca
-
수석 연구원:
- Sarah J. McKillop
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V6H 3V4
- 모병
- British Columbia Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 6477 604-875-2345
-
수석 연구원:
- Rebecca J. Deyell
-
-
Manitoba
-
Winnipeg, Manitoba, 캐나다, R3E 0V9
- 모병
- CancerCare Manitoba
-
연락하다:
- Site Public Contact
- 전화번호: 866-561-1026
- 이메일: ctu_web@cancercare.mb.ca
-
수석 연구원:
- Stephanie M. Villeneuve
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, 캐나다, A1B 3V6
- 모병
- Janeway Child Health Centre
-
수석 연구원:
- Lisa A. Goodyear
-
연락하다:
- Site Public Contact
- 전화번호: 709-777-8727
- 이메일: beverlyj.mitchell@easternhealth.ca
-
-
Nova Scotia
-
Halifax, Nova Scotia, 캐나다, B3K 6R8
- 모병
- IWK Health Centre
-
연락하다:
- Site Public Contact
- 전화번호: 902-470-8520
- 이메일: Research@iwk.nshealth.ca
-
수석 연구원:
- Chelsea Ash
-
-
Ontario
-
Hamilton, Ontario, 캐나다, L8N 3Z5
- 모병
- McMaster Children's Hospital at Hamilton Health Sciences
-
연락하다:
- Site Public Contact
- 전화번호: 905-521-2100
-
수석 연구원:
- Uma H. Athale
-
London, Ontario, 캐나다, N6A 5W9
- 모병
- Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 519-685-8306
-
수석 연구원:
- Shayna M. Zelcer
-
Ottawa, Ontario, 캐나다, K1H 8L1
- 모병
- Children's Hospital of Eastern Ontario
-
연락하다:
- Site Public Contact
- 전화번호: 613-737-7600
-
수석 연구원:
- Donna L. Johnston
-
Toronto, Ontario, 캐나다, M5G 1X8
- 모병
- Hospital for Sick Children
-
연락하다:
- Site Public Contact
- 전화번호: 416-813-7654
- 이메일: ask.CRS@sickkids.ca
-
수석 연구원:
- Daniel A. Morgenstern
-
-
Quebec
-
Montreal, Quebec, 캐나다, H3H 1P3
- 모병
- The Montreal Children's Hospital of the MUHC
-
연락하다:
- Site Public Contact
- 전화번호: 514-412-4445
- 이메일: info@thechildren.com
-
수석 연구원:
- Stephanie Mourad
-
Montreal, Quebec, 캐나다, H3T 1C5
- 모병
- Centre Hospitalier Universitaire Sainte-Justine
-
수석 연구원:
- Monia Marzouki
-
연락하다:
- Site Public Contact
- 전화번호: 514-345-4931
- 이메일: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, 캐나다, J1H 5N4
- 모병
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
연락하다:
- Site Public Contact
- 전화번호: 819-820-6480
- 이메일: crcinformation.chus@ssss.gouv.qc.ca
-
수석 연구원:
- Stephanie Vairy
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, 캐나다, S7N 0W8
- 모병
- Jim Pattison Children's Hospital
-
수석 연구원:
- Kathleen Felton
-
연락하다:
- Site Public Contact
- 전화번호: 306-655-3544
- 이메일: Jessica.Marien@saskhealthauthority.ca
-
-
-
-
-
San Juan, 푸에르토 리코, 00926
- 모병
- University Pediatric Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 787-474-0333
-
수석 연구원:
- Maria E. Echevarria
-
-
-
-
New South Wales
-
Randwick, New South Wales, 호주, 2031
- 모병
- Sydney Children's Hospital
-
수석 연구원:
- Draga Barbaric
-
연락하다:
- Site Public Contact
- 전화번호: (02) 9382-1721
-
Westmead, New South Wales, 호주, 2145
- 모병
- The Children's Hospital at Westmead
-
연락하다:
- Site Public Contact
- 전화번호: 61-2-9845 1400
-
수석 연구원:
- Bhavna Padhye
-
-
Queensland
-
South Brisbane, Queensland, 호주, 4101
- 모병
- Queensland Children's Hospital
-
수석 연구원:
- Steven A. Foresto
-
연락하다:
- Site Public Contact
- 전화번호: 61 7 3068 1111
-
-
Victoria
-
Parkville, Victoria, 호주, 3052
- 모병
- Royal Children's Hospital
-
수석 연구원:
- Martin A. Campbell
-
연락하다:
- Site Public Contact
- 전화번호: 61 3 9345 5656
- 이메일: Jordan.Hansford@rch.org.au
-
-
Western Australia
-
Perth, Western Australia, 호주, 6009
- 모병
- Perth Children's Hospital
-
연락하다:
- Site Public Contact
- 이메일: helpdesk@childrensoncologygroup.org
-
수석 연구원:
- Michelle Ng
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Patients must be enrolled on APEC14B1 and have consented to testing through the Molecular Characterization Initiative (MCI), prior to enrollment on ANBL2131
-
≤ 30 years at the time of initial diagnosis with high-risk disease
-
* Must have a diagnosis of neuroblastoma (NBL) or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamines
-
Newly diagnosed, high risk neuroblastoma (HRNBL) defined as one of the following:
- Any age with International Neuroblastoma Risk Group (INRG) Stage L2, MS, or M and MYCN amplification
- Age ≥ 547 days and INRG stage M regardless of biologic features (clinical MYCN testing not required prior to enrollment)
- Any age initially diagnosed with INRG Stage L1 MYCN amplified NBL who have progressed to stage M without systemic chemotherapy
- Age ≥ 547 days of age initially diagnosed with INRG Stage L1, L2, or MS who have progressed to stage M without systemic chemotherapy (clinical MYCN testing not required prior to enrollment)
-
-
Patients must have a body surface area (BSA) ≥ 0.25 m^2
-
No prior anti-cancer therapy except as outlined below:
- Patients initially recognized to have high-risk disease treated with topotecan/cyclophosphamide initiated on an emergent basis and within allowed timing, and with consent
- Patients observed or treated with a single cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (e.g., as per ANBL0531, ANBL1232 or similar) for what initially appeared to be non-high-risk disease but subsequently found to meet the criteria
- Patients who received localized emergency radiation to sites of life threatening or function-threatening disease prior to or immediately after establishment of the definitive diagnosis
-
Human immunodeficiency virus (HIV) -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
A serum creatinine based on age/sex as follows:
-
1 month to < 6 months: Male 0.4 mg/dL and female 0.4mg/dL
-
6 months to < 1 year: Male 0.5 mg/dL and female 0.5 mg/dL
-
1 to < 2 years: Male 0.6 mg/dL and female 0.6 mg/dL
-
2 to < 6 years: Male 0.8 mg/dL and female 0.8 mg/dL
-
6 to < 10 years: Male 1 mg/dL and female 1 mg/dL
-
10 to < 13 years: Male 1.2 mg/dL and female 1.2 mg/dL
-
13 to < 16 years: Male 1.5 mg/dL and female 1.4 mg/dL
-
≥ 16 years: Male 1.7 mg/dL and female 1.4 mg/dL
- The threshold creatinine values were derived from the Schwartz formula for estimating glomerular filtration rate (GFR) utilizing child length and stature data published by the Centers for Disease Control (CDC)
-
or a 24-hour urine creatinine clearance ≥ 70 mL/min/1.73 m^2 or
-
or a GFR ≥ 70 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method or direct small molecule clearance method (iothalamate or other molecule per institutional standard)
- Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility
-
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age
-
Serum glutamic pyruvic transaminase (SGPT) (Alanine aminotransferase [ALT]) ≤ 10 x ULN*
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
-
* Shortening fraction of ≥ 27% by echocardiogram, or
- Ejection fraction of ≥ 50% by echocardiogram or radionuclide angiogram
-
Ability to tolerate Peripheral Blood Stem Cell (PBSC) collection:
No known contraindication to PBSC collection. Examples of contraindications might be a weight or size less than the collecting institution finds feasible, or a physical condition that would limit the ability of the child to undergo apheresis catheter placement (if necessary) and/or the apheresis procedure
Exclusion Criteria:
- Patients who are 365-546 days of age with INRG Stage M and MYCN non-amplified NBL, irrespective of additional biologic features
- Patients ≥ 547 days of age with INRG Stage L2, MYCN non-amplified NBL, regardless of additional biologic features
- Patients with known bone marrow failure syndromes
- Patients on chronic immunosuppressive medications (e.g., tacrolimus, cyclosporine, corticosteroids) for reasons other than prevention/treatment of allergic reactions and adrenal replacement therapy are not eligible. Topical and inhaled corticosteroids are acceptable
- Patients with a primary immunodeficiency syndrome who require ongoing immune globulin replacement therapy
- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required prior to enrollment for female patients of childbearing potential
- Lactating females who plan to breastfeed their infants
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, food and drug administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
활성 비교기: Arm A (SOC treatment)
See detailed description |
Given IV
다른 이름들:
Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo bone marrow biopsy
다른 이름들:
Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo MRI
다른 이름들:
Undergo ECHO
다른 이름들:
Undergo MUGA
다른 이름들:
Undergo bone marrow aspiration Given IV
다른 이름들:
Undergo CT scan
다른 이름들:
Given IV
다른 이름들:
Undergo radiation therapy
다른 이름들:
Undergo blood and urine sample collection
다른 이름들:
Ancillary studies Given IV
다른 이름들:
Given IV Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo FDG PET
다른 이름들:
Undergo stem cell infusion
다른 이름들:
Given PO
다른 이름들:
Undergo apheresis
다른 이름들:
Undergo I-MIBG scan
다른 이름들:
Given PO or via NG or G tube
다른 이름들:
Undergo tumor resection surgery |
|
실험적: Arm B (Dinutuximab in induction)
See detailed description |
Given IV
다른 이름들:
Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo bone marrow biopsy
다른 이름들:
Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo MRI
다른 이름들:
Undergo ECHO
다른 이름들:
Undergo MUGA
다른 이름들:
Undergo bone marrow aspiration Given IV
다른 이름들:
Undergo CT scan
다른 이름들:
Given IV
다른 이름들:
Undergo radiation therapy
다른 이름들:
Undergo blood and urine sample collection
다른 이름들:
Ancillary studies Given IV
다른 이름들:
Given IV Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo FDG PET
다른 이름들:
Undergo stem cell infusion
다른 이름들:
Given PO
다른 이름들:
Undergo apheresis
다른 이름들:
Undergo I-MIBG scan
다른 이름들:
Given PO or via NG or G tube
다른 이름들:
Undergo tumor resection surgery |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Event free survival (EFS)
기간: Up to 3 years
|
EFS time is calculated from time of randomization to Arms A or B to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred. |
Up to 3 years
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
End of Induction (EOI) response rate
기간: From randomization to end of extended Induction, up to 12 months
|
The response rate will be calculated among all evaluable patients at end of Induction. Responders are defined as patients who achieve a >= partial response per the revised 2017 International Neuroblastoma Response Criteria (INRC) |
From randomization to end of extended Induction, up to 12 months
|
|
Overall survival (OS)
기간: Up to 3 years
|
OS time is calculated from time of randomization to Arms A or B until death, or until last contact if patient is alive. |
Up to 3 years
|
|
Incidence of adverse events
기간: Up to 2 years
|
The proportion of patients with at least one grade 3 or higher non-hematologic toxicity or grade 4 or higher hematologic toxicity during protocol therapy, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, will be reported. |
Up to 2 years
|
|
GD2 expression
기간: Up to 12 months
|
Dinutuximab binding to pre-therapy patient tumor samples will be measured and categorized as high or low. |
Up to 12 months
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Association between tumor and host factors and outcomes
기간: Up to 10 years
|
A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in Arms A and B to evaluate the relationship between tumor and host factors (including tumor ALK and other somatic mutations, copy-number aberrations, gene fusions, gene expression, and pathogenic germline variants) and chemo-immunotherapy during Induction with outcome. |
Up to 10 years
|
|
Circulating biomarkers and markers of minimal residual disease
기간: Up to 10 years
|
Will be assessed by comparing the proportion of patients with detectable vs. non-detectable tumor markers (including circulating tumor deoxyribonucleic acid, circulating free DNA, circulating tumor cells, and immune function profiling) between Arms A and B during and after induction and post-consolidation therapy using chi-squared tests at each individual time point, and Cochran's Q across time points to determine if there is a consistent difference in proportions between arms across time. In addition, the tumor markers will be analyzed as continuous variables using longitudinal data analysis methodology such as mixed effects models or generalized estimating equations as appropriate. |
Up to 10 years
|
|
Patterns of failure
기간: Up to 10 years
|
The impact of early or late chemoimmunotherapy during Induction on the probability of the involvement of a specific disease site at first relapse will be evaluated using Fisher's exact test. |
Up to 10 years
|
|
Effect of telomere maintenance mechanisms
기간: Up to 10 years
|
A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in arms A and B to evaluate the relationship between telomere maintenance mechanism and chemoimmunotherapy during Induction with outcome. Patients will be classified into 3 groups by telomere maintenance mechanism (TMM) based on messenger ribonucleic acid expression of TERT and analysis of telomeric DNA C-circles: telomerase (TERT) positive, alternative of lengthening of telomeres (ALT) positive, or no identified TMM. |
Up to 10 years
|
|
Functional and quality of life outcomes
기간: At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
|
Will descriptively summarize and compare the total Memorial Symptom Assessment Scale scores, total sub-domain scores, and individual symptom scores between patients randomized to receive dinutuximab during Induction (Arm B) to those of patients randomized to standard Induction (Arm A). |
At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
|
|
Adequacy of diagnostic biopsy specimens
기간: At time of tissue collection
|
Will be evaluated by descriptively comparing the successful delineation of histologic classification, MYCN amplification status, and ALK status via the traditional method of obtaining tissue for diagnosis, open surgical biopsy, versus the less invasive percutaneous core needle biopsy. |
At time of tissue collection
|
|
Associations between family-reported adverse social determinants of health and both clinical outcomes and biology
기간: Up to 10 years
|
Kaplan-Meier curves of EFS and OS will be generated and used to calculate 3-year EFS and OS estimates. Associations between social determinants of health (SDOH) and survival outcomes and time to receipt of dinutuximab will be evaluated with univariate and multivariate Cox proportional hazard models. Log-binomial regression will be used to estimate risk ratios and 95% CI for the occurrence of dinutuximab consent to randomization and therapy receipt by SDOH exposure. Effect modification of outcomes as a function of poverty, stratified by race/ethnicity, will be explored. |
Up to 10 years
|
|
Develop and validate deep learning predictors of Induction response (imaging objective)
기간: At diagnosis, EOI, during Extended Induction, and end of Extended Induction
|
Scans will be given as input to a convolutional neural network trained to predict EOI response. |
At diagnosis, EOI, during Extended Induction, and end of Extended Induction
|
|
Compare institutional versus central determination of overall response, individual response components, and PEIR and GEIR determination (imaging objective)
기간: Up to 10 years
|
Will be assessed by calculating the percentage of patients receiving the same EOI institutional and centrally reviewed determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and PEIR and GEIR. In addition, Cohen's kappa will be calculated to evaluate the concordance in each of these response measures. |
Up to 10 years
|
|
Incidence of late toxicities
기간: Up to 10 years
|
Will be addressed by calculating the proportion of treated patients with each late effect, including but not limited to impaired organ function, neuropsychiatric toxicity, and secondary malignancy. A 95% confidence interval will be placed on each proportion. |
Up to 10 years
|
|
Reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts
기간: Up to 10 years
|
The cumulative incidence of local progression (CILP) in patients with complete response of the primary site at EOI and GEIR on this study will be compared to the CILP rate of 11.2±1.8% observed on ANBL0532 using Gray's test. |
Up to 10 years
|
|
Post-transplant complications
기간: Up to 100 days post-transplant
|
Will be evaluated by calculating the incidence of endothelial injury complications and non-relapse mortality within 100 days of transplant, transplant-associated thrombotic microangiopathy (TA-TMA), severe TA-TMA, and sinusoidal obstruction syndrome (SOS) on Arms A and B and comparing between arms with a chi-squared test. The impact of TA-TMA occurrence on the timing or exclusion of subsequent therapy and interventions utilized to treat the TA-TMA, and associations with outcomes (EFS and OS) will be assessed. |
Up to 100 days post-transplant
|
|
Associations between end of induction (EOI) response and individual response components
기간: Up to 10 years
|
Log-rank tests will be used to explore the association between EOI response (using both the revised INRC and GEIR/PEIR classification) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS). |
Up to 10 years
|
|
Changes in image-defined risk factors (IDRF)
기간: Up to 10 years
|
The proportion of patients in the analytic cohort for whom each particular IDRF and also the presence of any IDRF is absent prior to surgical resection will be computed. McNemar's test for paired observations will be applied to determine whether there is a difference in the proportion of each IDRF and any IDRF present before and after initial therapy, and conditional logistic regression will be used to compare between treatment arms A and B. The IDRF status after initial therapy and whether there has been a change from diagnosis will be associated with surgical outcome (complete vs. incomplete resection, presence or absence of surgical complications) using chi-squared tests, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel test. The association of IDRF status with presence or absence of local failure after primary tumor resection will also be evaluated using a chi-squared test, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel. |
Up to 10 years
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Sara M Federico, Children's Oncology Group
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 신생물
- 조직학적 유형에 따른 신생물
- 신생물, 선상 및 상피
- 신생물, 신경상피
- 신경외배엽 종양
- 신생물, 생식 세포 및 배아
- 신생물, 신경 조직
- 신경외배엽 종양, 원시, 말초
- 신경외배엽 종양, 원시
- 신경 모세포종
- 신경절모세포종
- 조직 및 행정
- 보건 서비스 관리
- 아미노산, 펩티드 및 단백질
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 조사 기술
- 치료학
- 임상 실험실 기술
- 진단 기술 및 절차
- 진단
- 수술 절차, 수술
- Azoles
- 세포 학적 기술
- 세포 진단
- 레티노이드
- 카로티노이드
- 폴리 엔
- 알켄
- 탄화수소, acyclic
- 탄화수소
- 사이클로 헥 세네스
- 사이클로 헥산
- 사이클로 파라핀
- 탄화수소, alicyclic
- 탄화수소, 순환
- 테르펜
- 안료, 생물학적
- 생물학적 요인
- 탄수화물
- 물리적 현상
- Camptothecin
- 알칼로이드
- Podophyllotoxin
- 테트라 하이드로 나프탈렌
- 나프탈렌
- 다 환식 방향족 탄화수소
- 탄화수소, 방향족
- 다 환식 화합물
- 글루코 시드
- 글리코 사이드
- 다 카르 바진
- 트리아 젠
- 이미 다졸
- 이식
- 인돌
- 무기 화학 물질
- 염소 화합물
- 질소 화합물
- 조정 복합체
- 아미노산
- 강요
- 궤조
- 진단 기술, 수술
- 화학 기술, 분석
- 스펙트럼 분석
- 포스 포 아미드 머스타드
- 질소 머스타드 화합물
- 겨자 화합물
- 탄화수소, 할로겐화
- 포스 포 아미드
- 유기 인 화합물
- 금속, 무겁다
- Vinca 알칼로이드
- Secologanin Tryptamine 알칼로이드
- 인돌 알칼로이드
- 인돌리 지딘
- 인도인
- 안트라 사이클린
- 나프 타센
- 아미노 글리코 시드
- 백금 화합물
- Daunorubicin
- 전환 요소
- 세포 이식
- 세포 및 조직 기반 요법
- 생물학적 요법
- Cytapheresis
- 혈액 성분 제거
- 백혈구 감소 절차
- 세포 분리
- 페닐알라닌
- 아미노산, 방향족
- 아미노산, 순환
- 병원 관리
- 건강 시설 관리
- 트리 에틸 레네 포스 포 아미드
- 아 지리 딘
- 아 지린
- 비뇨기과 수술 절차
- 비뇨 생식기 외과 절차
- 테모졸로마이드
- 이리노테칸
- 시클로포스파미드
- 멜파란
- 에토포시드
- 카르보플라틴
- 독소루비신
- 빈크리스틴
- 시스플라틴
- 이소트레티노인
- 티오테파
- 토포테칸
- 1,2-디아미노사이클로헥산백금 II 구연산염
- 방사선 요법
- 방사
- 생검
- 시편 처리
- 자기 공명 분광법
- 백금
- DINUTUXIMAB
- 줄기 세포 이식
- 조혈 줄기 세포 이식
- 백혈구
- 핵 의학부, 병원
- 방광의 대형 요법 절제
기타 연구 ID 번호
기타 연구 ID 번호
- NCI-2023-08530
- U10CA180886 (미국 NIH 보조금/계약)
- NCI-2023-08530 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
- ANBL2131 (기타 식별자: CTEP)
- ANBL2131 (기타 식별자: Children's Oncology Group)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .